Generate Biomedicines (NASDAQ:GENB) Stock Rating Upgraded by Wall Street Zen

Generate Biomedicines (NASDAQ:GENB) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts have also commented on the company. Morgan Stanley upped their price objective on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. HC Wainwright boosted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Generate Biomedicines presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Trading Down 3.1%

Shares of GENB stock opened at $13.40 on Friday. Generate Biomedicines has a 52-week low of $11.00 and a 52-week high of $18.18. The firm has a market cap of $1.72 billion and a PE ratio of -12.52. The company has a 50-day moving average of $14.34.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.